Sanofi to buy Inhibrx in $2.2B deal

23 Jan 2024
www.pharmamanufacturing.com
AcquisitionPhase 2
Looking to get its hands on a promising rare disease candidate, Sanofi has agreed to acquire California-based Inhibrx.
The deal hinges on Inhibrx's phase 2 Alpha-1 Antitrypsin Deficiency (AATD)Alpha-1 Antitrypsin Deficiency (AATD) asset, INBRX-101. AATD is an inherited rare disease characterized by low levels of AAT protein, predominantly affecting the lung with progressive deterioration of the tissue. INBRX-101 is designed to reduce inflammation and prevent further deterioration of lung function in affected individuals, with less frequent (monthly vs. weekly) dosing.
As part of the deal, Sanofi will spin off all non-INBRX-101 assets — three sdAb-based therapeutic candidates currently being evaluated in trials against various cancers — into a new publicly traded company, New Inhibrx.
Per the deal, Sanofi will acquire all outstanding shares of Inhibrx for $30.0 per share in cash, representing an equity value of approximately $1.7 billion. The other pieces of the deal, which include Sanofi assuming inhibrx's outstanding debt and retaining an 8% equity interest in New Inhibrx, add up to a total transaction value of approximately $2.2 billion.
Looking to build its rare disease portfolio, Sanofi had signed a potential $750 million deal with Maze Therapeutics Back in May, to pick up its glycogen synthase 1 program, including its lead clinical candidate currently in development for the treatment of Pompe disease. Sanofi later abandoned the deal in December, following the FTC's move to block the acquisition.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.